Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Given that certain classes of gAPI’s such hemp derived CBD and terpenes might offer “relief” without the “high” THC provides, MyDx intends to partner with leaders in the industry to offer branded products without THC, akin to a “virgin” cocktail, if it finds that these formulations offer the benefits desired and the legal framework to sell them is viable.
In January of 2018, MyDx’s Biopharmaceutical division commenced clinical trials on its unique MyDx360 Pain Management Formula, appointed Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems and Diagnostics Veteran to its Executive Advisory Board on April 24, 2018, secured city and state legal cannabis manufacturing and distribution for its MyDx360 customers in May 2018, and featured the Eco Smart Pen working Prototype on CFN Media in August 2018. The MyDx Analyzer was selected to be used in a large HIV Study by the University of Florida in September 2018. MyDx recruited Mr. Cannabis Group to operate the Company in November 2018, onboarding a new experienced CFO/CEO (Mr. Matthew Bucciero), a leading Harvard neuroscientist (Just Vincent) to its scientific advisory board, and Mr. Erai Beckmann, a seasoned cannabis industry professional, as a member of the Board.
As previously disclosed, in July 2017, the Company and its CEO (collectively, the “Plaintiffs”) filed a lawsuit against Jerome Dewald and Skip Sanzeri. On or about July 9, 2018, the Company settled with Mr. Dewald and has dismissed the matter with prejudice as to Mr. Dewald. On or about July 25, 2018, the Company settled with Mr. Sanzeri, which settlement calls for settlement payments of $1,000 per month over the course of five months, after which the Company will dismiss the matter as to Mr. Sanzeri and fully dispose of the lawsuit. As of April 23, 2019, all five $1,000 payments have been made to the Company and the matter has "not yet" been dismissed.
In January of 2018, MyDx’s Biopharmaceutical division commenced clinical trials on its unique MyDx360 Pain Management Formula, appointed Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems and Diagnostics Veteran to its Executive Advisory Board on April 24, 2018, secured city and state legal cannabis manufacturing and distribution for its MyDx360 customers in May 2018, and featured the Eco Smart Pen working Prototype on CFN Media in August 2018. The MyDx Analyzer was selected to be used in a large HIV Study by the University of Florida in September 2018. MyDx recruited Mr. Cannabis Group to operate the Company in November 2018, onboarding a new experienced CFO/CEO (Mr. Matthew Bucciero), a leading Harvard neuroscientist (Just Vincent) to its scientific advisory board, and Mr. Erai Beckmann, a seasoned cannabis industry professional, as a member of the Board
SAN DIEGO, CA, Sept. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - MyDx, Inc. (OTC: MYDX), a leader in science based cannabis health technologies, is proud to announce that the University of Florida will be using our flagship product, the CannaDx Analyzer, in the largest prospective study to date focused on the health effects of marijuana in people living with HIV.
“With this study, we are taking an additional step in solidifying our position as a leader in science based cannabis health technologies. The CannaDx Analyzer is expected to be used in a large pre-clinical long term cannabis study that will track patient data,” stated Daniel Yazbeck, CEO of MyDx. “The science of cannabis is still in its infancy. Studies like these, conducted by reputable institutions like the University of Florida, and supported by MyDx, are paving the way for the future of cannabis science in this country.”
We first entered communications with the University of Florida back in December of 2017. After reviewing the CannaDx Analyzer’s specifications, abilities, and corresponding software application, we are happy to announce that our platform was the one selected for the study.
This is intended to be a long-term study to be conducted over the course of up to 5 years that has the potential to produce valuable data which could contribute to the future possibilities of cannabis being used as a real medicine.
Marijuana and Potential Long-term Effects Study Goals
The overarching goals of this study are to obtain evidence regarding the influence of marijuana on major health outcomes and behavior in persons living with HIV in order to help guide clinical recommendations and identify risk factors for consequences. The research team is especially interested in the relationship of marijuana to novel aspects of cognitive function (e.g. motivation, intention, planning) and to systemic inflammation.
The study will enroll 480 total participants, including 360 marijuana users and 120 non-users. Participants will be asked to complete a baseline visit, with yearly follow-up visits for up to five years.
During a visit, participants will be asked to:
Give a small blood sample
Give a small urine sample
Complete a 45-minute survey about their marijuana, alcohol, and drug use, sexual activity, pain levels, and mood
Complete approximately 2 hours of thinking and memory tasks on paper and on an iPad
The study would like to ask the participants to analyze the marijuana product that they consume using the MyDx device. This will be done by allowing participants to take the device home with a study phone that has the app on it to do a one-time test of their marijuana product. They will also enter some information in the app associated with their marijuana use (e.g., ailments trying to relieve, side effects).
The findings will inform HIV treatment providers and patients who are considering marijuana to manage HIV-related symptoms or the HIV disease itself, and will identify patterns of marijuana use that are most strongly associated with the incidence of substance use disorders.
The application of the MyDx analyzer in this study further solidifies our positioning of the company for a future exit
How's this picture http://sharc-research.org/2018/10/16/sharc-student-andrew-fiore-to-use-portable-marijuana-analyzer-in-pilot-study/ showing a STUDENT AT UNIVERSITY OF FLORIDA holding a CannaDx tester with the quote of
'We are excited to share that student Andrew Fiore will be pursuing the use of the CannaDx sensor in a limited pilot study to evaluate the interest of marijuana analyzers in research participants!
This project highlights SHARC’s leading research that works to answer pressing questions about marijuana use. We are excited to see to follow Andrew’s progress.
The use of this device should not be viewed as an endorsement or validation of the CannaDx sensor by SHARC or the University of Florida'
But I guess non believers could say thats not a real person or not a real CannaDx tester in his hand. Alleged Very FUNNY....
GANGA GOLD APP, POWERED BY MYDX:
ECO SMART PEN IS COMING:https://www.cannabisfn.com/cfnvideo/?id=lXSj78HA
Agree pps is dirt cheap, I really believe once pen launches and mydx announces multiple new partners we will see .01 or better. Holding on for the ride up.
I wonder what the buy to sell ratio is this morning, I think it's all BUYS. I guess we lost the posts lately of the buy to sell ratios - I wonder why, LOL..
Why is pps going up if MYDX was suppose to be in the trips, LOL. Looks like that was a WRONG call. IT'S COMING. Possible earnings tomorrow, could there be an update on Smart Pen Launch?
MYDX interview where Daniel says MYDX has a smart pen and mydx created a smart pen for Mr.Cannibas.
CFN Media Interviews MyDx Inc. (MYDX) at NCIA 2018 https://www.cannabisfn.com/cfnvideo/?id=lXSj78HA
MYDX video for anyone that has not seen it, from 3 views to 211 now, all in a matter of days, someone's watching:
I was glad to sticky 86111. DONE.
Yeah, I guess the mydx atm was broke today, lol. I guess mydx didn't hit trips today, lol. I guess we don't have an update on the buy to sell ratio today, lol. I guess there is no pen, lol. I guess we did not close UP 15 percent today, lol. Looks to me whoever was forced into selling for the past 11 days is out of shares, lol. You better believe 'IT'S COMING', not only coming but coming with NEW PARTNERS.
MYDX GREEN CLOSE - up 15 percent. The tide has turned. Earnings in 2 days unless delayed by a week.
Not Successful: LOL, SAN DIEGO, CA, Sept. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - MyDx, Inc. (OTC: MYDX), a leader in science based cannabis health technologies, is proud to announce that the University of Florida will be using our flagship product, the CannaDx Analyzer, in the largest prospective study to date focused on the health effects of marijuana in people living with HIV.
“With this study, we are taking an additional step in solidifying our position as a leader in science based cannabis health technologies. The CannaDx Analyzer is expected to be used in a large pre-clinical long term cannabis study that will track patient data,” stated Daniel Yazbeck, CEO of MyDx. “The science of cannabis is still in its infancy. Studies like these, conducted by reputable institutions like the University of Florida, and supported by MyDx, are paving the way for the future of cannabis science in this country.”
We first entered communications with the University of Florida back in December of 2017. After reviewing the CannaDx Analyzer’s specifications, abilities, and corresponding software application, we are happy to announce that our platform was the one selected for the study.
This is intended to be a long-term study to be conducted over the course of up to 5 years that has the potential to produce valuable data which could contribute to the future possibilities of cannabis being used as a real medicine.
Marijuana and Potential Long-term Effects Study Goals
The overarching goals of this study are to obtain evidence regarding the influence of marijuana on major health outcomes and behavior in persons living with HIV in order to help guide clinical recommendations and identify risk factors for consequences. The research team is especially interested in the relationship of marijuana to novel aspects of cognitive function (e.g. motivation, intention, planning) and to systemic inflammation.
The study will enroll 480 total participants, including 360 marijuana users and 120 non-users. Participants will be asked to complete a baseline visit, with yearly follow-up visits for up to five years.
During a visit, participants will be asked to:
Give a small blood sample
Give a small urine sample
Complete a 45-minute survey about their marijuana, alcohol, and drug use, sexual activity, pain levels, and mood
Complete approximately 2 hours of thinking and memory tasks on paper and on an iPad
The study would like to ask the participants to analyze the marijuana product that they consume using the MyDx device. This will be done by allowing participants to take the device home with a study phone that has the app on it to do a one-time test of their marijuana product. They will also enter some information in the app associated with their marijuana use (e.g., ailments trying to relieve, side effects).
The findings will inform HIV treatment providers and patients who are considering marijuana to manage HIV-related symptoms or the HIV disease itself, and will identify patterns of marijuana use that are most strongly associated with the incidence of substance use disorders.
The application of the MyDx analyzer in this study further solidifies our positioning of the company for a future exit
Todays number: mydxlife.com has received an estimated 22,700 visits over the last 30 days.
In January of 2018, MyDx’s Biopharmaceutical division commenced clinical trials on its unique MyDx360 Pain Management Formula, appointed Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems and Diagnostics Veteran to its Executive Advisory Board on April 24, 2018, secured city and state legal cannabis manufacturing and distribution for its MyDx360 customers in May 2018, and featured the Eco Smart Pen working Prototype on CFN Media in August 2018. The MyDx Analyzer was selected to be used in a large HIV Study by the University of Florida in September 2018. MyDx recruited Mr. Cannabis Group to operate the Company in November 2018, onboarding a new experienced CFO/CEO (Mr. Matthew Bucciero), a leading Harvard neuroscientist (Just Vincent) to its scientific advisory board, and Mr. Erai Beckmann, a seasoned cannabis industry professional, as a member of the Board.
I found the video doing a google search that I normally do about once a week. When I found it there were only 3 views. In the past I never saw the video before I found it last week, so don't know why it showed up last week, could be google never picked it up. Normally when I do the search I get 32 pages of results and then it stops, could have been after page 32 and just never showed up for me before.
MYDX interview where Daniel says MYDX has a smart pen and mydx created a smart pen for Mr.Cannibas.
CFN Media Interviews MyDx Inc. (MYDX) at NCIA 2018 https://www.cannabisfn.com/cfnvideo/?id=lXSj78HA
MYDX video for anyone that has not seen it, from 3 views to 200 now, all in a matter of days, someone's watching:
MYDX video about Ganja Gold is 8 months old, LOL, you could be right about age.
MYDX interview where Daniel says MYDX has a smart pen and mydx created a smart pen for Mr.Cannibas.
CFN Media Interviews MyDx Inc. (MYDX) at NCIA 2018 https://www.cannabisfn.com/cfnvideo/?id=lXSj78HA
MYDX video for anyone that has not seen it, from 3 views to 188 now, all in a matter of days, someone's watching:
The big news is that a lot of folks were saying that Yazbeck never filed for the PATENT. THIS IS PROOF THAT HE DID, CAN'T DISPUTE THAT.
OH MY: https://patents.justia.com/inventor/daniel-yazbeck
Patents by Inventor Daniel Yazbeck
Daniel Yazbeck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
PORTABLE DEVICE AND METHOD FOR VAPORIZING MATERIALS
Publication number: 20190014824
Abstract: A portable device, and more particularly a portable device for vaporizing materials such as oils for inhalation. Also, methods for vaporizing materials and methods of operating portable vaporizing devices. In addition, networks for providing operational features and/or instructions for operation of vaporizing devices and for monitoring and collecting operational data. In preferred embodiments, a vaporizing device and/or methods for operating a vaporizing device wherein the vaporizing device includes one or more of the following features: security features to regulate operation of the device; automatic detection of vaporizing material identity; user experience monitoring and data collection; and/or temperature adjustment of vaporizing material based on detected material for vaporization.
Type: Application
Filed: November 21, 2017
Publication date: January 17, 2019
Inventors: Daniel Yazbeck, Joshua Londano, James Panther, Jason Panther
$200,000 in stock value traded in just last 4 days. It's Coming.
MYDX interview where Daniel says MYDX has a smart pen and mydx created a smart pen for Mr.Cannibas.
CFN Media Interviews MyDx Inc. (MYDX) at NCIA 2018 https://www.cannabisfn.com/cfnvideo/?id=lXSj78HA
MYDX video for anyone that has not seen it:
I wonder if the folks that spent $370,000 on mydx stock in the last 12 days think the pps will go back. It's Coming...
LOL on post. Loving the volume and cheapies. No worry here, it's coming, just a little longer. Earnings next week if it's not delayed by a week.
I agree, volume has been huge lately. I believe something is in the works and your exactly correct that someone is getting the stock ready for a rally. Last 10 trading days were 188 million shares traded with a value of $315.000, all on a sub penny stock. It does look like to me someone is trying to accumulate as much as possible of the float before any news comes out.
Excellent pps to buy at.
LOL, I love that post....
I'm with you, I picked up 9 million more shares this week. No worries here at all.
5 million on the bid at 14, no sellers yet. I would think they would be selling into it if they still had shares to sell.
MYDX interview where Daniel says MYDX has a smart pen and mydx created a smart pen for Mr.Cannibas.
CFN Media Interviews MyDx Inc. (MYDX) at NCIA 2018 https://www.cannabisfn.com/cfnvideo/?id=lXSj78HA
MYDX video for anyone that has not seen it:
Buyer myself today.